What question did this study set out to answer?

To assess outcomes of patients with advanced gynaecologic malignancies enrolled in phase I trials over 13 years.

July 4, 2026Open Access

142P Early-phase clinical trials in gynaecologic malignancies: A 13-year single-center experience

Key Points

To assess outcomes of patients with advanced gynaecologic malignancies enrolled in phase I trials over 13 years.
Retrospective evaluation of patients with advanced gynaecologic cancers
Analysis of results from phase I trials at a single academic center
Duration of evaluation spans 13 years.
Patients exhibited clinical benefit from innovative agents in early-phase trials.
The study highlights the potential effectiveness of phase I trials in heavily pretreated populations.
Specific outcomes metrics are not detailed in the abstract.

Abstract

Patients (pts) with advanced gynaecologic cancers often progress after standard therapies. Phase I trials provide access to innovative agents and may offer clinical benefit in heavily pretreated populations. We retrospectively evaluated outcomes of pts enrolled in phase I trials at a single academic center over 13 years.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper